bioRxiv Science⌕ Search

bioRxiv · 10.1101/560458

Genetic inhibition of PCSK9, atherogenic lipoprotein concentrations, and calcific aortic valve stenosis

Abstract

BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition reduces plasma concentrations of low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB) and lipoprotein(a) [Lp(a)]. Atherogenic lipoprotein levels have been linked with calcific aortic valve stenosis (CAVS). Our objectives were to determine the association between variants in PCSK9 and lipoprotein-lipid levels, coronary artery disease (CAD) and CAVS, and to evaluate if PCSK9 could be implicated in aortic valve interstitial cells (VICs) calcification. MethodsWe built a genetic risk score weight for LDL-C levels (wGRS) using 10 independent PCSK9 single nucleotide polymorphisms and determined its association with lipoprotein-lipid levels in 9692 participants of the EPIC-Norfolk study. We investigated the association between the wGRS and CAD and CAVS in the UK Biobank, as well as the association between the PCSK9 R46L variant and CAVS in a meta-analysis of published prospective, population-based studies (Copenhagen studies, 1463 cases/101,620 controls) and unpublished studies (UK Biobank, 1350 cases/349,043 controls, Malmo Diet and Cancer study, 682 cases/5963 controls and EPIC-Norfolk study, 508 cases/20,421 controls). We evaluated PCSK9 expression and localization in explanted aortic valves by capillary Western blot and immunohistochemistry in patients with and without CAVS. Von Kossa staining was used to visualize aortic leaflet calcium deposits. PCSK9 expression under oxidative stress conditions in VICs was assessed. ResultsThe wGRS was significantly associated with lower LDL-C and apoB (p<0.001), but not with Lp(a). In the UK Biobank, the association of PCSK9 variants with CAD were positively correlated with their effects on apoB levels. CAVS was less prevalent in carriers of the PCSK9 R46L variant [odds ratio=0.71 (95% confidence interval, 0.57-0.88), p<0.001]. PCSK9 expression was elevated in the aortic valves of patients with aortic sclerosis and CAVS compared to controls. In calcified leaflets, PCSK9 co-localized with calcium deposits. PCSK9 expression was induced by oxidative stress in VICs. ConclusionGenetic inhibition of PCSK9 is associated with lifelong reductions in the levels of non-Lp(a) apoB-containing lipoproteins as well as lower odds of CAD and CAVS. PCSK9 is abundant in fibrotic and calcified aortic leaflets. Oxidative stress increases PCSK9 expression in VICs. These results provide a rationale for performing randomized clinical trials of PCSK9 inhibition in CAVS.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Perrot, N., Moschetta, D., Boekholdt, M., Valerio, V., Martinsson, A., Capoulade, R., Mass, E., Clavel, M.-A., Wareham, N. J., Dina, C., Chen, H. Y., Engert, J. C., Thanassoulis, G., Mathieu, P., Bosse, Y., Pibarot, P., Smith, J. G., Camera, M., Theriault, S., Poggio, P., Arsenault, B. J.. 2019-03-01. Genetic inhibition of PCSK9, atherogenic lipoprotein concentrations, and calcific aortic valve stenosis. https://doi.org/10.1101/560458

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Transportability of mouse gene knockout models to human complex phenotypes

Mouse gene knockout studies are a valuable resource for understanding human gene function and the mechanisms underlying disease. However, translating insights to humans requires causal similarities between mouse and human phenotypes. A mouse model is transportable if gene perturbations that impact the mouse phenotype also affect (in orthologous genes) the corresponding human phenotype of interest, with consistent directionality. To assess the transportability of mouse models to human complex traits we combined laboratory mouse gene perturbation data from the high-throughput International Mouse Phenotyping Consortium with predicted loss-of-function data from the UK Biobank within the Gene Perturbation Analysis for Transportability (GPAT) framework. Applying GPAT to 30 matched mouse-human phenotype pairs, we found evidence of transportability for 12 mouse phenotypes including biochemical (e.g. total cholesterol), cellular (e.g. lymphocyte counts) and anthropometric (e.g. length/height) phenotypes. In contrast, there was limited evidence for others such as fat mass and body mass index in the context of the murine experimental conditions. We also found some evidence of transportability of mouse glucose measurements to diabetes mellitus in humans. Genome-wide perturbation effects on matched phenotypes were on average positively correlated between mice and humans (meta-analysis GPAT P = 2.3x10-27). However, the degree of correlation was generally modest and heterogeneous across phenotypes with some gene perturbations strongly associated in both species in opposite directions. Our framework illustrates how perturbation data can be used to quantitatively validate experimental models for understanding human disease aetiology and highlights the need for a range of orthogonal model systems, which may include challenges and perturbations to the mouse knockouts, to interrogate the mechanistic basis of human genetic associations.

genetics↗

LRCQ: phenome-wide heritability enrichment of genomic loci from GWAS summary statistics

Some genetic variants are associated with many traits, but a variant's GWAS statistics are also inflated by the effects of variants in LD with it and by confounding shared by all variants in a study. Existing measures of per-variant pleiotropy, such as counts of significant associations or multi-trait association tests, do not separate these sources. Stratified LD score regression separates them for one trait at a time and only through predefined annotations. We present LRCQ (LD score regression on {chi}2 across many GWAS), which estimates for each locus its phenome-wide heritability enrichment: the variance of its causal effects across a set of traits, relative to an average locus. LRCQ regresses squared Z-scores from 30 or more GWAS jointly on squared LD, with per-trait LDSC intercepts and heritabilities fitted in earlier stages. Its pooled least-squares solution has a closed form whose cost does not grow with the number of traits. Its standard errors account for sample overlap and genetic correlation between GWAS. Squared Z-scores identify enrichment at the resolution of LD clumps, not single SNPs, so LRCQ reports clump-level estimates ("omni-loci"). These estimates can be aggregated over any functional annotation or gene set chosen after the analysis. In simulations with real UK Biobank LD and 30 to 1,000 traits, LRCQ was unbiased for its clump-level estimand. When GWAS share samples its test statistics are strongly right-skewed: normal-reference p-values were up to 10-fold anti-conservative at P < 0.001, and skewness-corrected p-values from the exact third cumulant restored type-I error and FDR control. Model-based standard errors were calibrated once the enrichment estimates plugged into them kept the polygenic background. It ranked enriched loci better than mean {chi}2, LD-normalised {chi}2, multi-trait omnibus tests and significant-association counts in 13 of 16 scenarios. Its main vulnerability was a misspecified LDSC intercept. Applied to 444 Pan-UK Biobank European-ancestry GWAS, LRCQ found strongly non-uniform phenome-wide enrichment: the SD of true clump-mean enrichment was 8.3, against a genome mean of 1. It identified 70 omni-loci (99 LD clumps) at FDR 5%, including CRP, CETP, APOB, AKTIP, SMOX, the SHBG region, CASZ1 and HNF1A. These ranked only moderately with mean {chi}2 and poorly with counts of significant associations. Gene-level phenome-wide enrichment rose with loss-of-function constraint. Phenome-wide heritability was 3-5-fold enriched in coding, conserved, 5' UTR and promoter sequence, and depleted in repressed chromatin. LRCQ turns hundreds of biobank GWAS into an LD-corrected map of where phenome-wide genetic variance lies, and complements its companion method LRCP, which estimates genetic-effect correlations between loci.

genetics↗